321 related articles for article (PubMed ID: 18281491)
1. Synergistic damage of tumor vessels with ultra low-dose endothelial-monocyte activating polypeptide-II and neovasculature-targeted tumor necrosis factor-alpha.
Crippa L; Gasparri A; Sacchi A; Ferrero E; Curnis F; Corti A
Cancer Res; 2008 Feb; 68(4):1154-61. PubMed ID: 18281491
[TBL] [Abstract][Full Text] [Related]
2. Endothelial monocyte activating polypeptide II (EMAP II) enhances the effect of TNF on tumor-associated vasculature.
Kayton ML; Libutti SK
Curr Opin Investig Drugs; 2001 Jan; 2(1):136-8. PubMed ID: 11527006
[TBL] [Abstract][Full Text] [Related]
3. Endothelial monocyte activating polypeptide II induces endothelial cell apoptosis and may inhibit tumor angiogenesis.
Berger AC; Alexander HR; Tang G; Wu PS; Hewitt SM; Turner E; Kruger E; Figg WD; Grove A; Kohn E; Stern D; Libutti SK
Microvasc Res; 2000 Jul; 60(1):70-80. PubMed ID: 10873516
[TBL] [Abstract][Full Text] [Related]
4. Tumour necrosis factor receptor I (p55) is upregulated on endothelial cells by exposure to the tumour-derived cytokine endothelial monocyte- activating polypeptide II (EMAP-II).
Berger AC; Alexander HR; Wu PC; Tang G; Gnant MF; Mixon A; Turner ES; Libutti SK
Cytokine; 2000 Jul; 12(7):992-1000. PubMed ID: 10880244
[TBL] [Abstract][Full Text] [Related]
5. Sensitization of tumor necrosis factor alpha-resistant human melanoma by tumor-specific in vivo transfer of the gene encoding endothelial monocyte-activating polypeptide II using recombinant vaccinia virus.
Gnant MF; Berger AC; Huang J; Puhlmann M; Wu PC; Merino MJ; Bartlett DL; Alexander HR; Libutti SK
Cancer Res; 1999 Sep; 59(18):4668-74. PubMed ID: 10493523
[TBL] [Abstract][Full Text] [Related]
6. EMAP-II facilitates TNF-R1 apoptotic signalling in endothelial cells and induces TRADD mobilization.
van Horssen R; Rens JA; Schipper D; Eggermont AM; ten Hagen TL
Apoptosis; 2006 Dec; 11(12):2137-45. PubMed ID: 17051333
[TBL] [Abstract][Full Text] [Related]
7. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration.
Curnis F; Sacchi A; Corti A
J Clin Invest; 2002 Aug; 110(4):475-82. PubMed ID: 12189241
[TBL] [Abstract][Full Text] [Related]
8. In vivo therapy of local tumor progression by targeting vascular endothelium with EMAP-II.
Schwarz RE; Schwarz MA
J Surg Res; 2004 Jul; 120(1):64-72. PubMed ID: 15172191
[TBL] [Abstract][Full Text] [Related]
9. In vivo sensitivity of human melanoma to tumor necrosis factor (TNF)-alpha is determined by tumor production of the novel cytokine endothelial-monocyte activating polypeptide II (EMAPII).
Wu PC; Alexander HR; Huang J; Hwu P; Gnant M; Berger AC; Turner E; Wilson O; Libutti SK
Cancer Res; 1999 Jan; 59(1):205-12. PubMed ID: 9892208
[TBL] [Abstract][Full Text] [Related]
10. Involvement of endothelial monocyte activating polypeptide II in tumor necrosis factor-alpha-based anti-cancer therapy.
Lans TE; Van Horssen R; Eggermont AM; Ten Hagen TL
Anticancer Res; 2004; 24(4):2243-8. PubMed ID: 15330168
[TBL] [Abstract][Full Text] [Related]
11. Crucial role for interferon gamma in the synergism between tumor vasculature-targeted tumor necrosis factor alpha (NGR-TNF) and doxorubicin.
Sacchi A; Gasparri A; Curnis F; Bellone M; Corti A
Cancer Res; 2004 Oct; 64(19):7150-5. PubMed ID: 15466213
[TBL] [Abstract][Full Text] [Related]
12. Endothelial monocyte-activating polypeptide-II (EMAP-II): a novel inducer of lymphocyte apoptosis.
Murray JC; Heng YM; Symonds P; Rice K; Ward W; Huggins M; Todd I; Robins RA
J Leukoc Biol; 2004 May; 75(5):772-6. PubMed ID: 14982944
[TBL] [Abstract][Full Text] [Related]
13. Apoptosis induced by a corneal-endothelium-derived cytokine.
Liu SH; Gottsch JD
Invest Ophthalmol Vis Sci; 1999 Dec; 40(13):3152-9. PubMed ID: 10586937
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13).
Curnis F; Sacchi A; Borgna L; Magni F; Gasparri A; Corti A
Nat Biotechnol; 2000 Nov; 18(11):1185-90. PubMed ID: 11062439
[TBL] [Abstract][Full Text] [Related]
15. Heparan sulfate regulates the antiangiogenic activity of endothelial monocyte-activating polypeptide-II at acidic pH.
Chang SY; Ko HJ; Heo TH; Kang CY
Mol Pharmacol; 2005 May; 67(5):1534-43. PubMed ID: 15710745
[TBL] [Abstract][Full Text] [Related]
16. Antitumor effect of endothelial monocyte-activating polypeptide-II on human prostate adenocarcinoma in mouse xenograft model.
Reznikov AG; Chaykovskaya LV; Polyakova LI; Kornelyuk AI
Exp Oncol; 2007 Dec; 29(4):267-71. PubMed ID: 18199981
[TBL] [Abstract][Full Text] [Related]
17. Endothelial-monocyte-activating polypeptide II induces migration of endothelial progenitor cells via the chemokine receptor CXCR3.
Hou Y; Plett PA; Ingram DA; Rajashekhar G; Orschell CM; Yoder MC; March KL; Clauss M
Exp Hematol; 2006 Aug; 34(8):1125-32. PubMed ID: 16863920
[TBL] [Abstract][Full Text] [Related]
18. Synergistic effect of platelet-activating factor and tumor necrosis factor-alpha on corneal myofibroblast apoptosis.
He J; Bazan HE
Invest Ophthalmol Vis Sci; 2006 Mar; 47(3):883-91. PubMed ID: 16505020
[TBL] [Abstract][Full Text] [Related]
19. Role of ATP synthase alpha subunit in low-dose endothelial monocyte-activating polypeptide-II-induced opening of the blood-tumor barrier.
Li Z; Liu YH; Xue YX; Xie H; Liu LB
J Neurol Sci; 2011 Jan; 300(1-2):52-8. PubMed ID: 21035144
[TBL] [Abstract][Full Text] [Related]
20. Regulation of EMAP II by hypoxia.
Matschurat S; Knies UE; Person V; Fink L; Stoelcker B; Ebenebe C; Behrensdorf HA; Schaper J; Clauss M
Am J Pathol; 2003 Jan; 162(1):93-103. PubMed ID: 12507893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
